MBX

Mayville Engineering Company Announces Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024
Automotive, Other Manufacturing, Engineering, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, General Automotive, Other Construction & Property, Residential Building & Real Estate, Defense, Commercial Building & Real Estate, Construction & Property, Military, Machinery, Machine Tools, Metalworking & Metallurgy, Performance & Special Interest, Off-Road Trucks & SUVs, Motorcycles, Aftermarket, Acquisition, MBX, Yoy, MSA, Investment, Share repurchase, Growth, Reddy, Adjustment, Hazel Park, Michigan, Automation, Public expenditure, UAW, EPS, Agriculture, MEC, Pharmaceutical industry

Mayville Engineering Company (NYSE: MEC) (the “Company” or “MEC”), a leading value-added provider of design, prototyping and manufacturing solutions serving diverse end markets, today announced results for the three and twelve-months ended December 31, 2023.

Key Points: 
  • Mayville Engineering Company (NYSE: MEC) (the “Company” or “MEC”), a leading value-added provider of design, prototyping and manufacturing solutions serving diverse end markets, today announced results for the three and twelve-months ended December 31, 2023.
  • Excluding the impact of the MSA acquisition, net sales increased organically by 6.1% year-over-year in the fourth quarter 2023.
  • Profit sharing, bonus and deferred compensation expense decreased $0.5 million to $3.6 million in the fourth quarter of 2023.
  • Free cash flow during the fourth quarter 2023 was $19.9 million as compared to ($0.7) million in the prior year period.

MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer

Retrieved on: 
Wednesday, November 1, 2023
Therapy, Biotechnology, Human resources, MBX, Parexel, Growth, Bausch, Michigan State University, Business administration, Bristol Myers Squibb, GSK, Culture, Ipsen, Bausch & Lomb, Management, Patient

CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer.

Key Points: 
  • CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer.
  • Ms. Graham is a seasoned global executive with 25+ years of experience leading human resources across a broad range of companies in the biopharmaceutical and healthcare industries.
  • “Michelle is an exceptionally experienced human resources executive with an impressive track record of leading global teams, developing and executing HR strategies, and fostering a diverse and inclusive culture,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “I am pleased to join the impressive MBX Biosciences team at this pivotal time in the company’s trajectory,” said Ms. Graham.

Mayville Engineering Company Announces Third Quarter 2023 Results

Retrieved on: 
Tuesday, October 31, 2023
Machine Tools, Metalworking & Metallurgy, Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Other Manufacturing, Adjustment, MEC, MSA, OEM, Mining, EV, ATV, Forestry, Certification, Acquisition, MBX, MUV, International Traffic in Arms Regulations, Growth, CARC, ITAR, Culture, Steel, Plastic, SIOP, Investment, Agriculture, Automation, Natural gas, Prefabrication, Bank, Management, 3D printing

Net sales to the construction & access market were $26.3 million in the third quarter 2023, a decrease of 2.3% versus the prior-year period.

Key Points: 
  • Net sales to the construction & access market were $26.3 million in the third quarter 2023, a decrease of 2.3% versus the prior-year period.
  • Net sales to the powersports market were $25.1 million in the third quarter of 2023, an increase of 7.7% versus the prior-year period.
  • Net sales to other end markets for the third quarter of 2023 were $23.5 million, an increase of 104.7% year-over-year.
  • During the third quarter 2023, the Company utilized free cash flow to repay $17.1 million of debt that it incurred in conjunction with the MSA acquisition.

MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, October 16, 2023
Annual general meeting, HP, Hypoparathyroidism, Pharmacokinetics, Food, MBX, PTH, Therapy, Society, PK, Death, Safety, American Society for Bone and Mineral Research, MAD, Disease, Participation, SC, SAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PD, Volunteering, Pharmacology, Patient, Pharmaceutical industry, Vaccine

CARMEL, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the presentation of positive results from its Phase 1 single and multiple ascending dose trial of MBX 2109 in healthy adults, as a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, held in Vancouver, Canada from October 13-16, 2023. MBX 2109 is the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP).

Key Points: 
  • MBX 2109 is the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP).
  • Single and repeat doses of MBX 2109 were generally well-tolerated, and the majority of treatment emergent adverse events were mild in severity.
  • The observed PK parameters following single and repeat doses of MBX 2109 reflected the intended prodrug design and support once-weekly dosing.
  • MBX Biosciences is preparing for an End-of-Phase 1 meeting with the U.S. Food and Drug Administration this quarter, and the company anticipates initiating its Phase 2 trial of MBX 2109 in patients with HP thereafter.

MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Retrieved on: 
Monday, October 9, 2023
PEP, Patient, Therapy, Pharmacokinetics, Safety, MBX, PBH, Pharmaceutical industry

“We are pleased to advance our second innovative PEP candidate, MBX 1416, into the clinic with the initiation of the Phase 1/2 clinical trial,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.

Key Points: 
  • “We are pleased to advance our second innovative PEP candidate, MBX 1416, into the clinic with the initiation of the Phase 1/2 clinical trial,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “This milestone is an important step toward bringing a potential solution to patients with PBH, for which there are no currently approved therapies.
  • The trial is being conducted in the United States and is designed to enroll approximately 56 participants.
  • More information on the Phase 1/2 study can be found at www.clinicaltrials.gov , identifier NCT06036784 .

MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

Retrieved on: 
Monday, September 11, 2023
Volunteering, PK, PEP, 3rd millennium, PD, Therapy, Hypoparathyroidism, Pharmacokinetics, PTH, MAD, FDA, Pharmacology, MBX, Safety, Pharmaceutical industry

CARMEL, Ind., Sept. 11, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109, the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP).

Key Points: 
  • “We are pleased with the positive and encouraging data seen throughout our Phase 1 program which we believe provides initial validation of the potential benefits of our PEP platform technology,” said Kent Hawryluk, president and chief executive officer of MBX Biosciences.
  • The primary endpoint was safety and tolerability, and secondary endpoints included PK and PD parameters.
  • Single and multiple ascending doses of MBX 2109 were observed to be generally well-tolerated.
  • Increases in albumin adjusted serum calcium and concomitant suppression of PTH(1-84) were observed in study participants treated once weekly with subcutaneously administered MBX 2109 for four doses.

Mayville Engineering Company to Introduce Strategy Update & Multi-Year Financial Targets at 2023 Investor Day

Retrieved on: 
Thursday, September 14, 2023
Machine Tools, Metalworking & Metallurgy, Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Other Manufacturing, Webcast, Growth, Hazel Park, Michigan, MEC, Acquisition, Marketing, MBX, Investment, NYSE, Share repurchase, Management, Retail

Within its presentation, MEC will also introduce new, three-year performance targets, as outlined below.

Key Points: 
  • Within its presentation, MEC will also introduce new, three-year performance targets, as outlined below.
  • “Today, we are introducing three-year performance targets that highlight the significant value creation potential of our business,” stated Jag Reddy, President and CEO of MEC.
  • The Company anticipates these actions will result in net sales growth of $170 to $240 million between year-end 2023 and year-end 2026.
  • Between year-end 2023 and year-end 2026, the Company anticipates that it will generate approximately $200 million in free cash flow.

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Retrieved on: 
Monday, August 7, 2023
Food, PEP, Investigational New Drug, FDA, Therapy, Hypoglycemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PBH, IND, MBX, Pharmaceutical industry

“IND clearance for MBX 1416 marks a significant milestone for our team, as we advance our second innovative PEP candidate into the clinic,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.

Key Points: 
  • “IND clearance for MBX 1416 marks a significant milestone for our team, as we advance our second innovative PEP candidate into the clinic,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “As a potential first-in-class therapy for PBH, we believe MBX 1416 may prevent severe hypoglycemia and its associated symptoms and meaningfully improve patients’ lives.
  • We look forward to initiating the Phase 1 trial later this quarter.”
    MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for PBH.
  • MBX expects to initiate enrollment in a Phase 1 trial in the third quarter of 2023 and anticipates reporting topline results in the second half of 2024.

Mayville Engineering Company Announces Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 1, 2023
Machine Tools, Metalworking & Metallurgy, Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Other Manufacturing, Plastic, SIOP, EV, International Traffic in Arms Regulations, CARC, Aluminium, Agriculture, ATV, MEC, Steel, Certification, MUV, Forestry, Acquisition, MSA, ITAR, Mining, Growth, OEM, Adjustment, MBX, Natural gas, Prefabrication, Management, 3D printing, Security (finance)

Net sales to the commercial vehicle market were $56.1 million in the second quarter of 2023, an increase of 1.7% versus the prior-year period.

Key Points: 
  • Net sales to the commercial vehicle market were $56.1 million in the second quarter of 2023, an increase of 1.7% versus the prior-year period.
  • Net sales to the construction & access market were $26.5 million in the second quarter 2023, a decrease of 9.8% versus the prior-year period.
  • Net sales to the powersports market were $24.0 million in the second quarter of 2023, an increase of 7.2% versus the prior-year period.
  • Net sales to the agriculture market were $13.4 million during the second quarter of 2023, a decrease of 12.5% versus the prior-year period.

MBX Expands Edge AI Hardware Portfolio with NVIDIA IGX Orin Platform

Retrieved on: 
Tuesday, July 18, 2023
Cortex, M150, BMC, Nvidia Jetson, S150, LPDDR5, 2U, TERA, IGX, PCI Express, Genomics, Optio, Machine, Google Images, NVENC, NVDEC, Micro Engineering Solutions, Sony Vaio S series, Ampere, NVIDIA, Dust, Linux, Quality control, Architecture, AI, ARM Cortex-A53, JPEG, MBX, Memory, GPU, Safety, Automation, GB, Medical device, Video game, Hatch

LIBERTYVILLE, Ill., July 18, 2023 /PRNewswire/ -- Leading custom hardware designer and integrator MBX Systems, recently acquired as the Engineered Solutions group of AHEAD, today announced eight new AI platforms for industrial and medical AI applications, including two high-performance systems powered by the new NVIDIA® IGX Orin™ platform. Software developers and IT solution providers developing applications with IGX Orin will have a choice of 2U and 4U form factors that can be deployed as edge rackmount servers, network attached workstations, or embedded systems within machines and devices, along with a range of sensor counts and compute power.

Key Points: 
  • LIBERTYVILLE, Ill., July 18, 2023 /PRNewswire/ -- Leading custom hardware designer and integrator MBX Systems , recently acquired as the Engineered Solutions group of AHEAD, today announced eight new AI platforms for industrial and medical AI applications, including two high-performance systems powered by the new NVIDIA® IGX Orin™ platform.
  • The expanded Optio series also includes two unique all-in-one AI systems with built-in inferencing powered by NVIDIA Jetson AGX Orin™ for medical inferencing without a separate monitor, plus two new and two previously announced embedded platforms designed with either NVIDIA Jetson AGX Orin or Jetson Orin NX™ to meet disparate edge AI needs.
  • With this range of system AI accelerators and form factors, the Optio portfolio offers the market's most comprehensive selection of hardware building blocks for edge AI applications in the industrial and medical sectors.
  • MBX also provides full AI application integration services as well as the market's most robust hardware lifecycle management capabilities through Hatch proprietary software.